Monitoring Anticoagulant Therapy by Activated Partial Thromboplastin Time: Hirudin Assessment

Summary

Background. Recombinant hirudin (RH) is a new anticoagulant for prophylaxis and treatment of venous and arterial thrombosis. To which extent the activated partial thromboplastin time (APTT) is suitable for monitoring of RH has not been properly evaluated. Recently, a capillary whole blood device was developed for bed-side monitoring of the APTT and it was demonstrated that this device was suitable to monitor heparin therapy. However, monitoring of RH was not evaluated.

Study Objectives. To evaluate in vitro and ex vivo the responsiveness and reproducibility for hirudin monitoring of the whole blood monitor and of plasma APTT assays, which were performed with several reagents and two conventional coagulometers.

Results. Large interindividual differences in hirudin responsiveness were noted in both the in vitro and the ex vivo experiments. The relationship between the APTT, expressed as clotting time or ratio of initial and prolonged APTT, and the hirudin concentration was nonlinear. A 1.5-fold increase of the clotting times was obtained at 150-200 ng/ml plasma. However, only a 2-fold increase was obtained at hirudin levels varying from 300 ng to more than 750 ng RH/ml plasma regardless of the assays. The relationship linearized upon logarithmic conversion of the ratio and the hirudin concentration. Disregarding the interindividual differences, and presuming full linearity of the relationship, all combinations were equally responsive to hirudin.

Conclusions. All assays were equally responsive to hirudin. Levels up to 300 ng/ml plasma can be reliably estimated with each assay. The manual device may be preferable in situations where rapid availability of test results is necessary.

• References

• 1 Hirudins: return of the leech. Editorial. Lancet 1992; 340: 579-580
• 2 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 3 Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Buller H, Hoet B, Bichler J, Close P. Biological effects of recombinant hirudin (CGP 39393) in human volunteers. JACC 1993; 22: 1080-1088
• 4 Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, Silling-Engelhardt G, Close P. Clinical pharmacology of intravenously administered recombinant desulfatohuridin (CGP 39393) in healthy volunteers. J Cardiovasc Pharm 1993; 22: 364-372
• 5 van den Besselaar AMHP, Meeuwisse-Braun J, Jansen-Griiter R, Bertina RM. Monitoring heparin therapy by the activated partial thromboplastin time. The effect of pre-analytical conditions. Thromb Haemost 1987; 57: 226-231
• 6 van den Besselaar AMHP, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63: 16-23
• 7 Bjomsson TD, Nash PV. Variability in heparin sensitivity of APTT reagents. Am J Clin Pathol 1986; 86: 199-204
• 8 Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent reproduced by the same manufacturer. Am J Clin Pathol 1988; 89: 19-23
• 9 Lucas FV, Duncan A, Jay R, Coleman R, Craft P, Chan B, Winfrey L, Mungall DR, Hirsh J. A novel whole blood capillary technic for measuring the prothrombin time. Am J Clin Pathol 1987; 88: 442-446
• 10 Ansell J, Holden A, Knapic RN. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. Arch Intern Med 1989; 149: 2509-2511
• 11 White RH, McCurdy SA, von Marensdorff H, Woodruff Jr DE, Lettgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. Ann Intern Med 1989; 111: 730-737
• 12 McCurdy SA, White RH. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. Arch Intern Med 1992; 152: 589-592
• 13 Ansell J, Tiarks C, Hirsh J, McGehee W, Adler D, Weibert R. Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. Am J Clin Pathol 1991; 95: 222-227
• 14 Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993; 70: 286-288